Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SanDiegoAlan, how close are you to La Mesa? Maybe you could personally knock on the door and give Koos our greetings so that he knows we are real people with concerns and its not all virtual reality out there through his computer screens.
Have no idea whether or not Harry Lander works out of the La Mesa office or not, but Koos should be there.
PS. Would be nice to know if Christine Ichim is still there developing the science for NR2F6 as well since last year we constantly heard of her travels for presentations and many of RGBP scientist connections were through her (studies and former work environments). We haven't heard anything regarding her for months.
Well, we are 3 months out from the Jan 26 HemaX ODD filing and a month removed from the March 23rd IND for tCellVax.
dCellVax IND response to FDA from current experiments was projected to be filed 2nd Qtr, so let's see what the next 2 months will bring.
Also, keep in mind that 1st Qtr financials should be out by mid May, but I'm not exactly looking forward to those.
Because they began trading last week. Good to stay abreast of at least important company news by regularly visiting the stock's Symbol on the finance section of a website like Yahoo.com
RGBP
Likewise
Schuller, is the dividend obligatory or as I seem to recall, it was worded that if they so choose to issue a dividend, one share preferred is entitled to ....?
Then the time is certainly ripe for news of significance. At least I hope so for everyone that still has shares here.
You have any second birthdays, anniversaries or the like today?
I'm ready for some good news. Been wondering why we haven't seen any news this year about scientific presentations or abstracts being prepared for any of the conferences including ACCR (going on now) that RGBP was a part of last year.
My hope is that they've progressed so far that they don't want to give away their research (i.e. trade secrets) until all is patented and/or because of negotiations with higher entities that want a deal and don't want the research to go public yet.
[Deep down there are still embers of hope, as I have to hope because I put so much money into this over the past 3 years].
Well, hopefully the various investment companies that wouldn't allow trading of RGBPP today will realize it and allow future trading.
I guess there wasn't any material news to report today other than the stock is now trading and available for some.
Well, we are fast approaching the 90th day since the filing of ODD for HemaXellerate as well as nearing the 30th day since the filing of tCellVax. dCellVax experiments are supposed to be completed this quarter, but we do not have an exact time frame.
I, for one, was not expecting preferred shares to be trading until further pipeline development had been completed. Do not know much about the strategy of issuing preferred. Obviously, issuing both common and preferred shares gives you options and has been interesting to see the emphasis seem to switch to preferred shares in recent company transactions.
If this emphasis change is part of a plan, then it seems we should be able to expect a PR within a short frame of time given one would think the launch of trading for preferred is somewhat based on a material development.
Just hope that material development is not ODD followed by the issuance of 500 million preferred shares at .05 in order to raise funds for clinical trials.
Here's my best guest theory on why no PR before RGBPP shares started trading.
Some have made comments about what a shame no PR to begin trading of preferred shares, RGBPP. But you have to think out of the box with this company.
Here's my theory:
Since Koos and company have millions of shares of RGBPP and will have to declare it as income I believe once it starts trading and has a value to it, they wouldn't necessarily want it to start trading at $10 or $1 or even .50. The lower it opens, the less value (income) they have to declare for tax purposes in 2016.
It is therefore to their significant tax savings to introduce the share price as low as possible (maybe they learned from RGBP's start at .50 and then immediate drop), then issue a PR afterwards (tonight, tomorrow) and have the shares run to where they might want or value them. In that way, they save tens of thousands in taxes and don't have to sell shares to pay their taxes, especially without a robust market into which they can sell their shares.
So, the activating of RGBPP preferred shares trading today, in a way that limited who could even bid/sell on the shares might very well have been a well thought out and planned one, to their own greatest benefit, especially since they don't have to buy shares, just sell them.
Well, that was an interesting 2 for 1 sale while it lasted (2 shares of preferred for the price of one common). And might be nice for our 2016 taxes if the value of RGBPP shows up as a dividend with value of .01/share at YE since I had to pay taxes on my RGBP dividend from the way it was filed with Scottrade at value of .50/share - crazy, but that was the first trade. So maybe with the .01/share first trade for RGBPP will save us some money in the end.
Hard to know what to make of this. Scottrade now trades RGBPP, after an initial delay, but TDA still will not accept an order even though the Stock symbol shows for other shares in the account.
Go figure. Sure will be nice if RGBPP climbs from here and doesn't return to .01/share.
But who can make sense of this morning's development? The fact that Koos and company gave themselves 10M shares in preferred shares as a bonus, not contracted milestone payment just before the preferred shares went live means something is in store. At .10/share, they each got a $1M bonus - nice and if price climbs the bonus goes up $1M for every ten cents.
One hopes that Lander is much better connected than Cavens if RGBP is to succeed.
Caven's investment firm's main two clients advertised on the company website are BMSN and RGBP. What has Cavens raised? - 750K on .025-.05 from Koos' own words in La Mesa interview are from friends, family, himself or acquaintances. In return, who knows how many shares he has, but he just got 10M more preferred.
Saguaro Clients
My hope was in Lander being a truly connected person who would give the company the business professionalism that it needed. I thought Koos was turning a page in the right direction. Now I'm anything but sure given the company's dealings.
Best not to remind us of Caven's background.
A reminder about Caven's background and I suspect Lander knows some well connected arab from his time in the Middle East.I would hope that they will find the money to start trials.
http://finance.yahoo.com/news/regen-biopharma-inc-expands-management-133000228.html;_ylt=AwrBT9EHxw9XHXsAw1NXNyoA;_ylu=X3oDMTByOHZyb21tBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzcg--
SAN DIEGO, CA--(Marketwired - Feb 17, 2015) - Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Except this time Koos and close associates are winning big, turning $50,000 loan/investments into $200,000-$600,000 potentially as they sell off released shares and can turn around and get more as the company needs more funding, plus have plenty of preferred to stock up on for when the science, which is good, has a payday.
RGBP will most likely be the last of the companies Koos needs to create with A/S of 800M preferred and A/S of 500M for common, plus he can add as he wants.
If Lander turns out like Cavens, just another pawn to play Koos' game in return for millions of shares, we will never see the benefit of all the really great scientific progress that the Ichims and others have moved forward.
I still hope I'm wrong, but these 8Ks are very hard to swallow or ignore.
By the way, the 30M shares do not seem to be "milestone" shares, as they are not mentioned or laid out in Lander's contract. Therefore, we must assume that they are merely bonus shares approved by the board, i.e. Koos.
Sorry, you can guarantee? And what will you put down for that "guarantee".
Agreed this is a speculative company, no lawsuit would be a challenge of that, but SEC filings and PRs and such are still subject to rules...
You may recall we went months in silence after HemaX retesting data went unaccepted by FDA and never had a clear PR regarding the fact that the dCellVax testing submitted was also rejected. So you don't think those were material events?
There are patterns of things here that would form a body of a complaint.
Twice bitten, I'm certainly not in a laughing mood this week unfortunately. I wish I could say that it was in light of something big, but I do not see any concrete indicators to believe that.
Preferred shares are not tradeable. Why issue bonus shares several months after the fact??? If these were truly milestone bonus shares due by contract and the FDA took off the hold on HemaXellerate back in December of 2015, then by contract, they should have received their bonus shares within I imagine 30-60 days at most. Why were they issued in April?
If it's because of a big event, it's an event that is going to benefit themselves the most, such as someone buying out the company for .15/share and a deal that compensates all holders of non-tradeable preferred shares at the same price. Sweet deal for them, (a 50% value increase for common shareholders at current pricing) and a cash win fall for Koos who has stuffed his pockets with millions of shares.
Any dreams of this going from .10 to $10 overnight on a buyout to me is just that, a dream.
Given the article on the investment website yesterday someone posted which showed RGBP in a very positive light, this volume looks like a post article rally that is being absorbed by the Angel and other investors with millions of shares selling into the rally, taking the opportunity to turn shares into cash.
At almost a million shares traded in the past 2 days, that type of volume trading, 5x the normal, would usually reward investors with a 20-30% gain, but instead, in spite of all the volume purchasing (which is a good thing), the price remains stagnant (not a good thing). But if you got shares from .025 - .05/share back in Jan-Mar 2015, you are doubling or quadrupling your money even at .10.
That's my gripe as you all know well. Other than this aspect, tremendous strides to move the science forward have taken place, but now I realize that might not be enough to cover my losses in this investment because there is absolutely nothing to prevent Koos, Cavens and Lander from issuing as many shares as they want to themselves. Koos is a company board of 1; all the scientists are advisory board members.
We'll probably know if we get another 8-K for another 30 million preferred shares issued to the big 3. Although maybe this time 5 million shares each would suffice.
Have to save room for the 10M shares each for dCellVax and possibly tCellVax and then milestone 10M shares for raising 10M dollars and another 10M that might be coming to Lander for the NIH and Lilly agreements.
LOL Actually, that came to my mind.
(sadly so)
Payoff shares for going along with the program? sigh.
SURE wish the announcement of his 10M preferred shares was for the milestone of having raised $10M from new sources as listed in his contract. But now that I even say that, why didn't I see before that that actually means their heads are in pennies even for preferred shares. If they had ever planned on preferred shares being of $1 value or more, how could you give someone 10M shares for raising $10M dollars? You'd be paying that person as much or more in shares than the money he raised.
But if their brains are fixed on the value of the company being in pennies and preferred shares only having a value of .10 or less, then 10M shares is a 10% bonus on the funds raised. Every penny more eats into the money raised sad to say.
aimo
No reply from Lander, no. I don't expect one. When I sent a positive email back in response to his open letter to shareholders, he contacted me within an hour, but I don't expect to hear anything.
What can he say?
Sorry DMort, I don't buy it. Koos gave himself special shares at the beginning of RGBP that had voting power of 10,000 to 1 for each share. His voting power against a takeover etc. was established from the beginning.
These shares have nothing to do with protection from a takeover as there is noone trying to take them over currently. Yes, I believe the science is good with tremendous potential (hopefully C. Ichim is still there, but it does concern me that after her research, abstracts, presentations were front and center throughout 2015, we have not heard anything about her or her research for months. June of this year is when the timeframe for her milestone shares becoming fully invested if she is still there as I hope she is).
Have you looked at the financials since they began handing out the .05 common shares. What will the impact of these millions of preferred shares have when they begin trading and have to account for them financially?
Cavens and Lander were hired supposedly for their financial prowess and ability with connections to raise funds (i.e. capital investment to propel the company forward). Instead what we have seen is the selling of the company to itself, largely with unregistered shares (hmmm SEC listing) at values that mock every shareholder who has to put hard earned cash into shares. WHY. What successful company are they imitating?
Here are the main terms of Harry Lander's agreement according to 8K filed Oct 13, 2015 upon his hiring. There is no mention of 10M shares upon clearance of HemaX from FDA hold. Rather, it states 10M shares upon completion of Phase II trials for any of the pipeline products. He got another 10M preferred shares which vest 2 years after hire date, just for coming on board and drawing a salary of $200,000/yr. How many of you have been invested for 2 years and got nothing?
Since the listing of ways Lander can gain 10M preferred shares seems incomplete, who knows how many shares he'll end up with. But he has not accomplished one of those milestones listed below yet, for which he is guaranteed another 10M preferred shares.
On October 9, 2015 Regen entered into a written employment agreement with Dr. Lander whereby Dr. Lander Caven shall serve as President of Regen ("Agreement"). The Term of this Agreement shall commence on November 15, 2015 and shall expire on November 14, 2018.
Pursuant to the Agreement, Dr. Lander shall be paid salary at the rate of $16,667 per month . Pursuant to the Agreement Dr. Lander shall receive:
(a) 1,000,000 newly issued Series A Preferred shares of Regen ("Signing Shares"). Signing Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by Dr. Lander ("Transfer Restriction") until after a one year vesting period has expired.
(b) 10,000,000 newly issued Series A Preferred shares of Regen ("Incentive Shares"). Incentive shares shall vest to Dr. Lander two years from the date he is hired.
(c) 10,000,000 newly issued Series A Preferred shares of Regen ("Milestone Shares ") upon any of the following events having occurred during the employment by Regen of Dr. Lander:
A) two collaborations with pharmaceutical firms with annual revenues of $250,000,000 or greater over their last three fiscal years
B) an equity raise of $10,000,000 invested in the securities of Regen by sources introduced to Regen by Dr. Lander and who have not previously been introduced to Regen by any other entity.
C) Listing of Regen's equity securities on any of the following markets:
i. Nasdaq Global Select Market
ii. Nasdaq Global Market
iii. Nasdaq Capital Market
iv. The New York Stock Exchange
v. NYSE MKT
d) sale of a portion of the Regen Intellectual Property portfolio for appropriate consideration
e) clearance of any Regen sponsored intellectual property through FDA phase II clinical trials.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1
Dmort, the numbers don't add up. How can you dream of preferred shares being valued at $100 in a buyout? That would mean the big 3 just gave themselves bonuses of $1B each for getting HemaX approved for clinical trials. How does that make sense?
Lilly is not "on board". The agreement allows RGBP to submit entries into Lilly's compound research and of course to do so, Lilly in return has the right to buy or license compounds they get interested in. It's a good thing, but it's on parallel with the NIH research agreement. It's not a billion dollar deal.
At the rate preferred shares (the share of choice) are currently going out the door, a buyout of RGBP might get no more the $1-$2 preferred share and that is a couple years down the line, after who knows how many shares are released.
Question, how many shares need to be issued at .01-.05 to fully fund a 3 phase clinical trial for one pipeline drug?
I think you guys are really off base at this point.If Lilly is on board wouldnt it be cheaper for them to buy RGBP ? Shareholders get paid off.At that point a lawsuit might be smart.Preferred shares may get $100 a share,those that gave themselves millions prior to a sale would be liable.For Lilly to finalize the deal they would want any litigation resolved
Interesting. Starting my research on SEC and investigations. The SEC's home page has this listing:
Common violations that may lead to SEC investigations include:
Misrepresentation or omission of important information about securities
Manipulating the market prices of securities
Stealing customers' funds or securities
Violating broker-dealers' responsibility to treat customers fairly
Insider trading (violating a trust relationship by trading on material, non-public information about a security)
Selling unregistered securities.
Anyone know if someone who has signed a confidentiality agreement with a company can testify against that company if subpoenaed by the prosecutor?
Koos has everyone sign confidentiality agreements, even people he talks to and that is probably one reason he has lasted this long without having to change his ways.
But if a SEC investigation was begun, could people like past president Christopher Mizer, and T. Ichim and C. Ichim, if she is no longer there testify openly about Koos and his agenda in court, or would they legally still be bound by their confidentiality agreements?
That's the problem. The hope was that in hiring scientists in house in 2015 and then bringing the science forward and Lander coming in with all the other scientific board members, that the company was finally maturing beyond Koos' cash machine.
With all the shares he has already, all he needs to become rich is act like a legitimate company with legitimate investment pricing and share purchasing and this could go big and help everyone.
But at the rate of these transactions, the only ones to profit in the end will be those will millions of shares because the PPS will never be able to rise with the financials taking 10's of millions in loses on paper because of issuing undervalued shares, especially at 90% discounts.
So Sage, the common shares for RGBP (which have been trading between .10 and .25 for a long time) have 128M shares O/S and we've been waiting for over 2 years for HemaX trials to be approved and get started, but they don't have any money.
Why, because while we pay .10-.40/share, the insiders and great fundraisers with connections (supposedly) and big backgrounds in taking companies to higher trading platforms etc. have been trading shares for .05 and under piecemeal to friends and then spending it.
Now, to keep common shares down and who knows what future plans are in line to benefit themselves, they are issuing Preferred shares (shares that trump our shares legally) not at premium pricing, but as low as .01/share and that doesn't cause you concern? The fact that they given themselves bonuses on top of shares on pennies to where now preferred shares issued are almost as many as common shares which means the company "float" is going to be over 250 million and rapidly climbing to where RGBP might have 1 Billion in O/S between common and preferred and still not have enough money to carry trials to term. Lets' say you have 100,000 shares for which you've paid $15,000-$20,000 or more when O/S were 50M. What's the real value of those shares when float hits 1B and no treatment is yet for sale?
That sounds like good business. Can you name one successful company out there that sold shares only to insiders for 2 years at 60-90% discounts and ended up succeeding?
Why does this article show up on these other websites, but not as a headline for the stock on places like Yahoo Finance? Yahoo finance has PR today for 8-K listing all the shares given out, but not the relationship with Lily.
Anyone comment on why that would be?
If that is possible and its happens, more than a lawsuit might be in order. Just look at a chart of trading for RGBP in connection to Feb 16th transaction with Lily that was not released to the public.
Stock price quickly doubled on high volume (.10-.20) on news that wasn't released, only then to be sold back down to .10 where we then have a public release of information. I'm sure the SEC might find who bought and sold during the past 30 days a bit interesting.
After all, if insider trading is illegal, who suddenly bought all those shares and then again, who started selling heavily into the rising price?
This continued display of greed and total disregard for the value of the company and its shareholders for transactions that only benefit the chosen few insiders if not illegal, certainly seems close to it, especially in light of the public, official open letter to shareholders of what the company's plans were to be.
I have patience for scientific development. I have patience for interruptions and setbacks encountered in honest endeavors. I have very little patience for those who lie or deceive and that taste is coming from the continued practices revealed in these filings. In light of that fact, I have sent the following:
Dear Mr. Landers,
Our hope was that your arrival would put RGBP in a more professional, business mode of fair practices regarding the transactions of RGBP. Your open-letter to shareholders in January acknowledged the highly discounted shares given out to Koos, friends and family that have made the financial filings a huge red flag to any serious outside and stable investor. This was promised to be ending in Q1 of 2016.
Yet, days before Q1 ended, shares were handed out not only at the rate of .05/share, but even lower to the lowest level of .0125/share for preferred! How is that an improvement?
Now today, we shareholders are informed that not only have the big 3 handed themselves 10,000,000 preferred shares (at a rate of over $1,000,000 a person is price of preferred shares are only equal to common shares, but as further insult to shareholders, $10,000 of debt is offset for .01/preferred share price with 1,000,000 preferred shares. This is crazy. Many of the shareholders that invested in this company from BMSN on have invested far more than $10,000 and we do not have close to 1,000,000 common shares for our money. I don’t think the SEC smiles on companies who may fill out the proper forms, but whose business practices raise many flags.
As these practices continue to the sole benefit of a few insiders and to the devaluation of every shareholder on a preposterous scale, please reflect on the fact that litigation is not out of the question on behalf of shareholders as public company promises are not held and totally disregarded.
I once had great hopes for this company, but the more transactions I see, the less hope I have for this company as a true company. Rather, more and more it appears as an organization with some great science, but hell bent on securing the rewards of a few insiders.
Extremely disappointed in this recent 8-K
And preferred shares at that. Inexcusable and extremely disappointing development. At 10M shares each (What has Todd Cavens done over the past 3 years other than sell shares at 60%-80% below market value which shows up as millions of dollars in company losses on the financials while he and friends cash in for 10x the paid value.
I'm sorry to have to admit that it might not matter that the science becomes gold. By the time Koos and company pay themselves off with shares, the dilution will be so great that they themselves may reap hundreds of millions each while the investment of shareholders at .20 still run a loss.
Extremely frustrating and the giving away of 1,000,000 preferred shares - those are shares legally considered as more valuable than the ones we have bought between.10-.40, were sold at .01/share. The company values its own preferred shares at .01/share to the world in public documents. But what do they care, at .01/share, 10 million shares still have a $100,000 value and there is absolutely nothing that can stop them from giving themselves tens of millions of shares each year or several times a year.
The only thing that might stop this eventually is a class action lawsuit. If we lose our shirts, they should too.
Certainly an interesting day trading wise. High volume, not a news day and while a lot of shares trading with the price down a bit, not really what you would call a sell-off and much of volume is buying at sale price and not bid price per Level II.
Someone accumulating. They release the good news of IND and price goes no where, then the sour news of more undervalued shares given out and now, a high volume day of trading. If this closes to the green at .15 or above, my guess and it's only a guess is that ODD notification has come in and we will see news on it within 4 days.
dMort, How can you say this?
IF you read this Board frequently you would know that there has been NO dilution.
Harry.Lander@regenbiopharma.com
To put on the clinical trials of HemaXellerate, you need money. Cash is necessary as you won't find a hospital willing to take preferred A shares that won't trade. Clearly the shares being issued are not with the scope of raising the necessary funds for a clinical trial, so they must be hoping or planning on getting that cash in another way.
Orphan Drug Status will certainly help, but if they were in a hurry, they could have filed the paperwork on that months ago without waiting for FDA approval first.
My interpretation of what has transpired thus far is that while HemaX was the first IND and certainly they wanted to complete the work and get FDA approval, the focus of money and energy right now is to advance the NR2F6 studies and IND as fast as possible since the scope and financial rewards of a cancer curing IND vastly outweigh the scope of HemaX and aplastic anemia, so while HemaX has value, NR2F6 has much much more and if they can raise funds, interest for collaboration of NR2F6, whether through NIH or someone else, they will also have the funds to move HemaX forward into clinical trials, but as of now, they don't have the cash and we haven't seen the evidence yet that they have the connections or ability to raise those funds.
Summary of shares sold in 1st Qtr (and No, RGBP never sold shares for .15 or .20, those were both at .05/share. You have to take the value paid and divide by the total number of shares).
1/28/2016 .05/share (2M common, 1M preferred A) for $150,000
1/29-2/2 .025/share (300K common, 300K preferred A) for $15,000
2/22/2016 .05/share (666K common, 333K preferred A) for $50,000
3/22/2016 .0125/shre (1M common, 3M preferred A) for $50,000
Totals: 3,966,000 common, 4,633,000 preferred A for $265,000
While I was expecting those from Jan-Feb, I must say the March transaction stinks of the same or worse in light of the open letter. At $265,000 raised, these transactions are not meant to fund the clinical trials, but are more of the friends and family plan and what is worse, the lowest price per share (yes, you have to give at least equal value to preferred shares, because in liquidation, they come first and no one would agree to buy them unless there was a concrete plan to be able to trade them in future). The fact that the company just value their common and preferred shares to the world at .0125 when the stock was trading at .13-.14/share communicates that as a company, we are setting up our personal accounts for profitteering and have little interest in doing deals that reflect the value of shareholders.
For what we've had to pay to accumulate shares, we should each have hundreds of thousands or millions of shares when compared to the insider transactions. This is Koos' stamp and Lander's has a failing grade on this recent March transaction which does nothing to benefit the company as a whole and is all about personal gain.
How cutting edge are "checkpoint inhibitors"?
I decided to look into how far along "checkpoint inhibitor" research is and while this is anything but conclusive, I found it interesting that the American Cancer Society only lists 2 areas of checkpoint inhibitors that have been approved (with many others showing promising research). Neither of the other 2 areas (PD-1/PD-L1 or CTLA-4) deal with NR2F6.
American Cancer Society checkpoint inhibitors for cancer treatment
This seems to indicate that RGBP is on the cutting edge of something with great promise and as yet, not very much established in the line of treatments. It also means that if NR2F6 turns out to be an important checkpoint inhibitor for cancer stem cell differentiation, as they suspect, RGBP will have critical patents worth a lot of money already established in this area.
RGBP might not be the DT dream stock for flipping anymore, but the dots are lining up to make a much better long term picture.
Worth reading again the PR on Jan 20th about the new collaboration of RGBP with NIH/NCATS
SAN DIEGO, January 20, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (RGBP) and (RGBP) announced today that the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), and Regen have entered into a formal research collaboration agreement to jointly explore the biology of the NR2F6 protein.
Specifically, the collaboration will focus on identifying ligands for the nuclear receptor NR2F6 using Regen's patented screening methodology and the sophisticated expertise and unique chemical libraries of NCATS. A ligand is a substance that forms a complex with a biomolecule to serve a biological purpose.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify agonists and antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system.
"Regen is entering into a new phase as it is now both a clinical stage company and one with a promising pipeline of research," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen Biopharma. "One of our goals for 2016 is to rapidly move our small molecule screening program forward, and collaborating with world experts in this field is part of our strategy. Our collaborator at NCATS, Dr. Menghang Xia is a research scientist with vast experience in assay development, compound screening and probe/ligand identification."
"We have a very defined, strategic implementation plan for 2016 and we have every intention of executing it successfully," said David Koos, Ph.D., Chairman and CEO of Regen. "This screening program, which is growing quickly, is an important element to our strategy of developing a novel checkpoint inhibitor."
Was just going to post a similar idea.
2nd Qtr was outlined as the time of the most important announcements/developments in Lander's Open Letter:
- End of highly discounted share offerings (previously .025/share or 60%-80% off trading price). This was to end within 1st Qtr (only another week to go)
- 2nd Qtr dCellVax response filing to FDA based on experiments being conducted by Dr. Kesari at John Wayne Cancer Research Center
- Initial filing of a new IND regarding NR2F6 inhibition. (Recent PRs announced the completion of their initial testing with positive results)
And while the open letter didn't list a time frame for HemaXellerate Orphan Drug Status, we expect that announcement at any time.
So we have 3 significant events anticipated in the 2nd Qtr for the ongoing development and increased valuation of the company as well as hoping for other unknown positive developments (whether collaborations, discovering at NCATS, grants from NIH etc.)
It's hard to wait, but the 2nd qtr is going to be very important for whether or not the company continues to move forward.
Also, all the Ichims' incentive share vestiture deadline is June 2016 (3 INDs, 3 CRO relationships etc.)
Can't say the heavy volume to downside is an encouraging sign.
They filed for Orphan Drug status on Jan 26, so we should hear something soon.